HeartBeam Inc. (NASDAQ: BEAT), a medical technology company specializing in cardiac care innovation, announced it will host a conference call on May 13, 2026, at 4:30 p.m. Eastern time to discuss its first-quarter financial results for the period ended March 31, 2026, and provide updates on key growth initiatives. These include its limited commercial launch for arrhythmia assessment, extended-wear patch development, heart attack detection, and artificial intelligence programs.
The company's 3D ECG technology, which received FDA clearance for arrhythmia assessment in December 2024 and for 12-lead ECG synthesis software in December 2025, is designed to enable cable-free ECG signal collection from three non-coplanar directions. This platform technology synthesizes signals into a 12-lead ECG, allowing physicians to identify cardiac health trends and acute conditions outside of medical facilities. HeartBeam holds over 20 issued patents related to its technology.
The upcoming earnings call will be a key event for investors seeking to understand the company's progress toward commercializing its innovative cardiac monitoring solutions. The limited commercial launch for arrhythmia assessment marks a significant step toward broader market adoption, while the extended-wear patch and heart attack detection programs aim to expand the company's product portfolio. Additionally, HeartBeam's AI initiatives are expected to enhance data analysis and diagnostic capabilities.
Interested parties can access the full press release at https://ibn.fm/yN939. For more information about HeartBeam and its technology, visit the company's website at https://www.heartbeam.com/indications for cleared indications for use.
